Compare Eli Lilly And Co (LLY) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Nvidia Corp — how do they compare? Eli Lilly And Co trades at $1,177.75 (market cap $1.04T), while Nvidia Corp trades at $229.39 (market cap $5.57T). The key difference: Nvidia Corp is far larger — about 5.4× Eli Lilly And Co's market cap, and Eli Lilly And Co pays the higher dividend (0.59%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Nvidia Corp for 115 Days on average.
| LLY | NVDA | |
|---|---|---|
Market Cap | $1.04T | $5.57T |
Volume | 3,064,878 | 117,720,595 |
Sector | Health | Technology |
52-Week High | $1.28K | $239.27 |
52-Week Low | $799.57 | $165.17 |
Typical Hold Time | 93 Days | 115 Days |
Enterprise Value | $1.09T | $5.54T |
Dividend Yield | 0.59% | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
NVIDIA (NVDA) trades at $229.28, down 3.4% today, but maintains strong fundamentals with revenue surging to $130.5B in 2025 and net income reaching $72.88B. The stock shows a bullish technical signal with support at $228 and resistance at $235. Recent earnings beats and a 75.95% analyst buy rating highlight continued growth momentum despite the day's decline.
Outlook remains positive with a consensus price target of $339.17, offering 48% upside. Key risks include increased competition in AI chips and market volatility, but NVIDIA's dominant market position and accelerating AI demand support long-term growth potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
